Ziopharm Oncology Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$277.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Ziopharm Oncology's estimated annual revenue is currently $11.7M per year.(i)
  • Ziopharm Oncology's estimated revenue per employee is $201,000
  • Ziopharm Oncology's total funding is $277.7M.
  • Ziopharm Oncology's current valuation is $204.5M. (January 2022}

Employee Data

  • Ziopharm Oncology has 58 Employees.(i)
  • Ziopharm Oncology grew their employee count by -54% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M347-5%$634MN/A
#2
$50.9M253N/AN/AN/A
#3
$39.6M197-12%N/AN/A
#4
$11.6M2140%$506.4MN/A
#5
$4360M37257175%N/AN/A
#6
$16.3M81N/AN/AN/A
#7
$37.2M185N/AN/AN/A
#8
$3.2M16N/AN/AN/A
#9
$5.6M28-3%N/AN/A
#10
$888.2M44190%N/AN/A

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.

keywords:N/A

$277.7M

Total Funding

58

Number of Employees

$11.7M

Revenue (est)

-54%

Employee Growth %

$204.5M

Valuation

N/A

Accelerator

Ziopharm Oncology News

2022-04-20 - Allogene, Progenity, Adaptive Phage Tout New Top Executives

... he served on the Board of Directors at Ziopharm Oncology and held ... Clover Oncology: LiongHo Chua was appointed president of Greater...

2022-04-17 - Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer

Additionally, he served on the Board of Directors at Ziopharm Oncology, and held roles of increasing responsibility at Biogen, Bristol-Myers...

2022-03-30 - CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

Prior to Ziopharm Oncology, Dr. Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics,...

2021-02-25 - Fol­low biotechs go­ing pub­lic with the End­points News IPO Track­er

Laurence Cooper has done his part. In the five years since he left a tenured position at Houston’s MD Anderson Cancer Center to become CEO of Boston-based Ziopharm, he’s steered the small-cap immunotherapy player through patient deaths in trials, clinical holds, short attacks and, most recently ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.3M580%$0.663M
#2
N/A5821%N/A
#3
$7.3M58-17%N/A
#4
$11.7M58115%$174M
#5
$11M58N/AN/A